<!DOCTYPE html>
<html lang="en">

<head>
  <meta charset="utf-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1, user-scalable=no" />
  <link href="./styles/custom-styles.min.css" rel="stylesheet">
  <title>Banner</title>
  <link rel="icon" href="data:,">

  <!-- ad size meta tag -->
  <meta name="ad.size" content="width=300,height=600">

  <!-- click tags -->
  <script type="text/javascript">
    var clickTag = "https://www.cancertherapyadvisor.com/custom/edetail/opdivo-rcc/#/";
    var clickTag2 = "https://packageinserts.bms.com/pi/pi_opdivo.pdf";
    var clickTag3 = "https://packageinserts.bms.com/pi/pi_yervoy.pdf";
  </script>
</head>

<body>
  <div class="bannerWrapper">
    <div class="banner__frame banner__frame--one">
      <div class="banner__frame--top">
        <div class="banner__frame--header" >
          <p>Content is sponsored by Bristol Myers Squibb.</p>
        </div>
        <div class="banner__frame--logo">
          <div class="logo__left">
            <img src="img/opdivo-yervoy-logo.svg" alt="OPDIVO + YERVOY Logo" />
          </div>
          <div class="logo__right">
            <img src="img/cta-logo.svg" alt="CTA Logo" />
          </div>
        </div>
        <div class="banner__frame--top-body">
          <div class="h2">
            Could OPDIVO® + YERVOY® <br />be appropriate for your <br />patients with aRCC?
          </div>
          <div class="banner__frame--footnote">
            <p>
              aRCC=advanced renal cell carcinoma.
            </p>
          </div>
        </div>
      </div>
    </div>
    <div class="banner__frame banner__frame--two">
      <div class="banner__frame--top">
        <div class="banner__frame--header" >
          <p>Content is sponsored by Bristol Myers Squibb.</p>
        </div>
        <div class="banner__frame--logo">
          <div class="logo__left">
            <img src="img/opdivo-yervoy-logo.svg" alt="OPDIVO + YERVOY Logo" />
          </div>
          <div class="logo__right">
            <img src="img/cta-logo.svg" alt="CTA Logo" />
          </div>
        </div>
        <div class="banner__frame--top-body">
          <div class="h2">
            Join a virtual rep to<br /> review clinical trial<br /> data ...
          </div>
        </div>
      </div>
    </div>
    <div class="banner__frame banner__frame--three">
      <div class="banner__frame--top">
        <div class="banner__frame--header" >
          <p>Content is sponsored by Bristol Myers Squibb.</p>
        </div>
        <div class="banner__frame--logo">
          <div class="logo__left">
            <img src="img/opdivo-yervoy-logo.svg" alt="OPDIVO + YERVOY Logo" />
          </div>
          <div class="logo__right">
            <img src="img/cta-logo.svg" alt="CTA Logo" />
          </div>
        </div>
        <div class="banner__frame--top-body">
          <div class="h2">
            ... including 8 years of<br />follow-up efficacy<br />data and safety.
          </div>
        </div>
      </div>
    </div>
    <div class="banner__frame banner__frame--four">
      <a href="javascript:void(window.open(window.clickTag))">
        <div class="banner__frame--top">
          <div class="banner__frame--header" >
            <p>Content is sponsored by Bristol Myers Squibb.</p>
          </div>
          <div class="banner__frame--logo">
            <div class="logo__left">
              <img src="img/opdivo-yervoy-logo.svg" alt="OPDIVO + YERVOY Logo" />
            </div>
            <div class="logo__right">
              <img src="img/cta-logo.svg" alt="CTA Logo" />
            </div>
          </div>
          <div class="banner__frame--top-body">
            <div class="h2">Review the data.</div>
            <button class="btn">LEARN MORE</button>
          </div>
        </div>
      </a>
    </div>

    <div class="bottomSectionOuter">
      <div id="IsiContent">
        <div class="outer">
  <div class="one" id="autoScrollBanners">
    <div id="scroll_cont" class="iScrollContainer">
      <div id="scroll" class="iScrollVerticalScrollbar iScrollLoneScrollbar">
        <div id="scroll_indicator" class="iScrollIndicator">
          <div id="scroll_fix" class="iScrollLoneScrollbarFix"></div>
        </div>
      </div>
    </div>
    <script>
      var sbih = 'undefined';
      if (sbih !== 'undefined') {
        document.getelementbyid('scroll_indicator').style.height = sbih;
      }
    </script>
    <div>
      <div class="mianContentScroller">
        <div id="scroller">
          <div id="scroll_fix" class="iScrollLoneScrollbarFix"></div>
          <div class="banner__frame--bottom">
            <div class="banner__frame--text">
              <div class="indicationBody">
                <div class="indication">INDICATION</div>
                <p class="indicationCopy">OPDIVO® (nivolumab), in combination with YERVOY® (ipilimumab), is indicated for the first-line treatment of adult patients with intermediate or poor risk advanced renal cell carcinoma (RCC).</p>
                <div class="h3">IMPORTANT SAFETY INFORMATION</div>
                <p><b>Severe and Fatal Immune-Mediated Adverse Reactions</b><br />Immune-mediated adverse reactions listed herein may not include all possible severe and fatal immune-mediated adverse reactions.</p>
                <p>Immune-mediated adverse reactions, which may be severe or fatal, can occur in any organ system or tissue. While immune-mediated adverse reactions usually manifest during treatment, they can also occur after discontinuation of OPDIVO or YERVOY. Early identification and management are essential to ensure safe use of OPDIVO and YERVOY. Monitor for signs and symptoms that may be clinical manifestations of underlying immune-mediated adverse reactions. Evaluate clinical chemistries including liver enzymes, creatinine, adrenocorticotropic hormone (ACTH) level, and thyroid function at baseline and periodically during treatment with OPDIVO and before each dose of YERVOY. In cases of suspected immune-mediated adverse reactions, initiate appropriate workup to exclude alternative etiologies, including infection. Institute medical management promptly, including specialty consultation as appropriate.</p>
                <p>
                  Withhold or permanently discontinue OPDIVO and YERVOY depending on severity (please see section 2 Dosage and Administration in the accompanying Full Prescribing Information). In general, if OPDIVO or YERVOY interruption or discontinuation is required, administer systemic corticosteroid therapy (1 to 2 mg/kg/day prednisone or equivalent) until improvement to Grade 1 or less. Upon improvement to Grade 1 or less, initiate corticosteroid taper and continue to taper over at least 1 month. Consider administration of other systemic immunosuppressants in patients whose immune-mediated adverse reactions are not controlled with corticosteroid therapy. Toxicity management guidelines for adverse reactions that do not necessarily require systemic steroids (e.g., endocrinopathies and dermatologic reactions) are discussed below.
                </p>
                <p><u>Immune-Mediated Pneumonitis</u><br /> OPDIVO and YERVOY can cause immune-mediated pneumonitis. The incidence of pneumonitis is higher in patients who have received prior thoracic radiation. In patients receiving OPDIVO 3 mg/kg with YERVOY 1 mg/kg every 3 weeks, immune-mediated pneumonitis occurred in 3.9% (26/666) of patients, including Grade 3 (1.4%) and Grade 2 (2.6%).</p>
                <p><u>Immune-Mediated Colitis</u><br /> OPDIVO and YERVOY can cause immune-mediated colitis, which may be fatal. A common symptom included in the definition of colitis was diarrhea. Cytomegalovirus (CMV) infection/reactivation has been reported in patients with corticosteroid-refractory immune-mediated colitis. In cases of corticosteroid-refractory colitis, consider repeating infectious workup to exclude alternative etiologies. In patients receiving OPDIVO 3 mg/kg with YERVOY 1 mg/kg every 3 weeks, immune-mediated colitis occurred in 9% (60/666) of patients, including Grade 3 (4.4%) and Grade 2 (3.7%).</p>
                <p><u>Immune-Mediated Hepatitis and Hepatotoxicity</u><br /> OPDIVO and YERVOY can cause immune-mediated hepatitis. In patients receiving OPDIVO 3 mg/kg with YERVOY 1 mg/kg every 3 weeks, immune-mediated hepatitis occurred in 7% (48/666) of patients, including Grade 4 (1.2%), Grade 3 (4.9%), and Grade 2 (0.4%).</p>
                <p><u>Immune-Mediated Endocrinopathies</u><br /> OPDIVO and YERVOY can cause primary or secondary adrenal insufficiency, immune-mediated hypophysitis, immune-mediated thyroid disorders, and Type 1 diabetes mellitus, which can present with diabetic ketoacidosis. Withhold OPDIVO and YERVOY depending on severity (please see section 2 Dosage and Administration in the accompanying Full Prescribing Information). For Grade 2 or higher adrenal insufficiency, initiate symptomatic treatment, including hormone replacement as clinically indicated. Hypophysitis can present with acute symptoms associated with mass effect such as headache, photophobia, or visual field defects. Hypophysitis can cause hypopituitarism; initiate hormone replacement as clinically indicated. Thyroiditis can present with or without endocrinopathy. Hypothyroidism can follow hyperthyroidism; initiate hormone replacement or medical management as clinically indicated. Monitor patients for hyperglycemia or other signs and symptoms of diabetes; initiate treatment with insulin as clinically indicated.</p>
                <p>In patients receiving OPDIVO 3 mg/kg with YERVOY 1 mg/kg every 3 weeks, adrenal insufficiency occurred in 7% (48/666) of patients, including Grade 4 (0.3%), Grade 3 (2.5%), and Grade 2 (4.1%).</p>
                <p>In patients receiving OPDIVO 3 mg/kg with YERVOY 1 mg/kg every 3 weeks, hypophysitis occurred in 4.4% (29/666) of patients, including Grade 4 (0.3%), Grade 3 (2.4%), and Grade 2 (0.9%).</p>
                <p>In patients receiving OPDIVO 3 mg/kg with YERVOY 1 mg/kg every 3 weeks, thyroiditis occurred in 2.7% (22/666) of patients, including Grade 3 (4.5%) and Grade 2 (2.2%).</p>
                <p>In patients receiving OPDIVO 3 mg/kg with YERVOY 1 mg/kg every 3 weeks, hyperthyroidism occurred in 12% (80/666) of patients, including Grade 3 (0.6%) and Grade 2 (4.5%).</p>
                <p>In patients receiving OPDIVO 3 mg/kg with YERVOY 1 mg/kg every 3 weeks, hypothyroidism occurred in 18% (122/666) of patients, including Grade 3 (0.6%) and Grade 2 (11%).</p>
                <p>In patients receiving OPDIVO 3 mg/kg with YERVOY 1 mg/kg every 3 weeks, diabetes occurred in 2.7% (15/666) of patients, including Grade 4 (0.6%), Grade 3 (0.3%), and Grade 2 (0.9%).</p>
                <p><u>Immune-Mediated Nephritis with Renal Dysfunction</u><br /> OPDIVO and YERVOY can cause immune-mediated nephritis. In patients receiving OPDIVO 3 mg/kg with YERVOY 1 mg/kg every 3 weeks, immune-mediated nephritis with renal dysfunction occurred in 4.1% (27/666) of patients, including Grade 4 (0.6%), Grade 3 (1.1%), and Grade 2 (2.2%).</p>
                <p><u>Immune-Mediated Dermatologic Adverse Reactions</u><br /> OPDIVO can cause immune-mediated rash or dermatitis. Exfoliative dermatitis, including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug rash with eosinophilia and systemic symptoms (DRESS) has occurred with PD-1/PD-L1 blocking antibodies. Topical emollients and/or topical corticosteroids may be adequate to treat mild to moderate nonexfoliative rashes. </p>
                <p>YERVOY can cause immune-mediated rash or dermatitis, including bullous and exfoliative dermatitis, SJS, TEN, and DRESS. Topical emollients and/or topical corticosteroids may be adequate to treat mild to moderate non-bullous/exfoliative rashes.</p>
                <p>Withhold or permanently discontinue OPDIVO and YERVOY depending on severity (please see section 2 Dosage and Administration in the accompanying Full Prescribing Information).</p>
                <p>In patients receiving OPDIVO 3 mg/kg with YERVOY 1 mg/kg every 3 weeks, immune-mediated rash occurred in 16% (108/666) of patients, including Grade 3 (3.5%) and Grade 2 (4.2%).</p>
                <p><u>Other Immune-Mediated Adverse Reactions</u><br /> The following clinically significant immune-mediated adverse reactions occurred at an incidence of &lt;1% (unless otherwise noted) in patients who received OPDIVO monotherapy or OPDIVO in combination with YERVOY or were reported with the use of other <span class="noWrap" >PD-1/PD-L1</span> blocking antibodies. Severe or fatal cases have been reported for some of these adverse reactions: <i>cardiac/vascular:</i> myocarditis, pericarditis, vasculitis; <i>nervous system:</i> meningitis, encephalitis, myelitis and demyelination, myasthenic syndrome/myasthenia gravis (including exacerbation), Guillain-Barré syndrome, nerve paresis, autoimmune neuropathy; <i>ocular:</i> uveitis, iritis, and other ocular inflammatory toxicities can occur; <i>gastrointestinal:</i> pancreatitis to include increases in serum amylase and lipase levels, gastritis, duodenitis; <i>musculoskeletal and connective tissue:</i> myositis/polymyositis, rhabdomyolysis, and associated sequelae including renal failure, arthritis, polymyalgia rheumatica; <i>endocrine:</i> hypoparathyroidism; <i>other</i> <i>(hematologic/immune):</i> hemolytic anemia, aplastic anemia, hemophagocytic lymphohistiocytosis (HLH), systemic inflammatory response syndrome, histiocytic necrotizing lymphadenitis (Kikuchi lymphadenitis), sarcoidosis, immune thrombocytopenic purpura, solid organ transplant rejection, other transplant (including corneal graft) rejection.</p>
                <p>In addition to the immune-mediated adverse reactions listed above, across clinical trials of YERVOY monotherapy or in combination with OPDIVO, the following clinically significant immune-mediated adverse reactions, some with fatal outcome, occurred in &lt;1% of patients unless otherwise specified: <i>nervous system:</i> autoimmune neuropathy (2%), myasthenic syndrome/myasthenia gravis, motor dysfunction; <i>cardiovascular:</i> angiopathy, temporal arteritis; <i>ocular:</i> blepharitis, episcleritis, orbital myositis, scleritis; <i>gastrointestinal:</i> pancreatitis (1.3%); <i>other</i> <i>(hematologic/immune):</i> conjunctivitis, cytopenias (2.5%), eosinophilia (2.1%), erythema multiforme, hypersensitivity vasculitis, neurosensory hypoacusis, psoriasis.</p>
                <p>Some ocular IMAR cases can be associated with retinal detachment. Various grades of visual impairment, including blindness, can occur. If uveitis occurs in combination with other immune-mediated adverse reactions, consider a Vogt-Koyanagi-Harada–like syndrome, which has been observed in patients receiving OPDIVO and YERVOY, as this may require treatment with systemic corticosteroids to reduce the risk of permanent vision loss.</p>
                <p><b>Infusion-Related Reactions</b><br /> OPDIVO and YERVOY can cause severe infusion-related reactions. Discontinue OPDIVO and YERVOY in patients with severe (Grade 3) or life-threatening (Grade 4) infusion-related reactions. Interrupt or slow the rate of infusion in patients with mild (Grade 1) or moderate (Grade 2) infusion-related reactions. In RCC patients receiving OPDIVO 3 mg/kg with YERVOY 1 mg/kg every 3 weeks, infusion-related reactions occurred in 5.1% (28/547) of patients.</p>
                <p><b>Complications of Allogeneic Hematopoietic Stem Cell Transplantation</b><br /> Fatal and other serious complications can occur in patients who receive allogeneic hematopoietic stem cell transplantation (HSCT) before or after being treated with OPDIVO or YERVOY. Transplant-related complications include hyperacute graft-versus-host-disease (GVHD), acute GVHD, chronic GVHD, hepatic veno-occlusive disease (VOD) after reduced intensity conditioning, and steroid-requiring febrile syndrome (without an identified infectious cause). These complications may occur despite intervening therapy between OPDIVO or YERVOY and allogeneic HSCT.</p>
                <p>Follow patients closely for evidence of transplant-related complications and intervene promptly. Consider the benefit versus risks of treatment with OPDIVO and YERVOY prior to or after an allogeneic HSCT.</p>
                <p><b>Embryo-Fetal Toxicity</b><br /> Based on its mechanism of action and findings from animal studies, OPDIVO and YERVOY can cause fetal harm when administered to a pregnant woman. The effects of YERVOY are likely to be greater during the second and third trimesters of pregnancy. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with OPDIVO and YERVOY and for at least 5 months after the last dose.</p>
                <p><b>Increased Mortality in Patients with Multiple Myeloma when OPDIVO is Added to a Thalidomide Analogue and Dexamethasone</b><br /> In randomized clinical trials in patients with multiple myeloma, the addition of OPDIVO to a thalidomide analogue plus dexamethasone resulted in increased mortality. Treatment of patients with multiple myeloma with a PD-1 or PD-L1 blocking antibody in combination with a thalidomide analogue plus dexamethasone is not recommended outside of controlled clinical trials.</p>
                <p><b>Lactation</b><br /> There are no data on the presence of OPDIVO or YERVOY in human milk, the effects on the breastfed child, or the effects on milk production. Because of the potential for serious adverse reactions in breastfed children, advise women not to breastfeed during treatment and for 5 months after the last dose.</p>
                <p><b>Serious Adverse Reactions</b><br /> In Checkmate 214, serious adverse reactions occurred in 59% of patients receiving OPDIVO plus YERVOY (n=547). The most frequent serious adverse reactions reported in ≥2% of patients were diarrhea, pyrexia, pneumonia, pneumonitis, hypophysitis, acute kidney injury, dyspnea, adrenal insufficiency, and colitis.</p>
                <p><b>Common Adverse Reactions</b><br /> In Checkmate 214, the most common adverse reactions (≥20%) reported in patients treated with OPDIVO plus YERVOY (n=547) were fatigue (58%), rash (39%), diarrhea (38%), musculoskeletal pain (37%), pruritus (33%), nausea (30%), cough (28%), pyrexia (25%), arthralgia (23%), decreased appetite (21%), dyspnea (20%), and vomiting (20%).</p>
                <p class="copyRight">
                  Please see US Full Prescribing Information for <a  href="javascript:void(window.open(window.clickTag2))">OPDIVO</a> and <a  href="javascript:void(window.open(window.clickTag3))">YERVOY</a>.
                </p>
                <p class="pt-4-0" >&copy; 2024 Bristol-Myers Squibb Company.<br />
                  OPDIVO®, YERVOY® and the related logos are registered trademarks of Bristol-Myers Squibb Company.</p>
                <p class="copyRightBottom">7356-US-2400427 08/24</p>
              </div>
            </div>
          </div>
        </div>
      </div>
    </div>
  </div>
  <div class="banner__frame--footer">
    <a href="javascript:void(window.open(window.clickTag2))">Full Prescribing Information for OPDIVO</a>
    <a href="javascript:void(window.open(window.clickTag3))">Full Prescribing Information for YERVOY</a>
  </div>
  <script type="text/javascript">
    const loadbefore = document.getElementById("autoScrollBanners");
    var functionIsRunning = false;
    let conf;
    loadbefore.addEventListener("wheel", (event) => {
      if (functionIsRunning == false) {
        manualscroll();
        functionIsRunning = true;
      }
    }, { passive: false });
    loadbefore.addEventListener("click", (event) => {
      if (functionIsRunning == false) {
        manualscroll();
        functionIsRunning = true;
      }
    }, { once: false });
    loadbefore.addEventListener("touchstart", (event) => {
      if (functionIsRunning == false) {
        manualscroll();
        functionIsRunning = true;
      }
    }, { passive: false });
    function manualscroll() {
      conf = {
        scrollTime: 105900, // in milliseconds
        scrollDelay: 0,    // in milliseconds
        scrollType: 'manual',
      }
      loaded();
    }
    function autoscroll() {
      functionIsRunning = true;
      conf = {
        scrollTime: 155900, // in milliseconds
        scrollDelay: 0,    // in milliseconds
        scrollType: 'all',
      }
      loaded();
    }

    function loaded() {
      // console.log('000')
      const ua = window.navigator.userAgent
      const browserIsIE = ua.indexOf('Trident/') > -1;
      const autoScroll = {
        isProcess: false,
        transformInterval: 300,
        timeSpend: 0
      }
      const isi = {
        wrapper: document.getElementById('autoScrollBanners'),
        scroller: document.getElementById('scroller'),
        scrollDiff: document.getElementById('autoScrollBanners').scrollHeight - document.getElementById(
          'autoScrollBanners').clientHeight,
        prevTouchY: 0,
        prevOffTop: 0,
        calcScrollDiff: function () {
          this.scrollDiff = this.scroller.clientHeight - this.wrapper.clientHeight;
        }
      }
      const scrollBar = {
        isHeightCorrected: false,
        container: document.getElementById('scroll_cont'),
        el: document.getElementById('scroll'),
        indicator: document.getElementById('scroll_indicator'),
        scale: 0,
        indicatorHeight: 0,
        lastTouchY: 0,
        lastEventY: 0,
        calc: function () {
          const sbBoundingHeight = this.el.getBoundingClientRect().height;
          this.scale = sbBoundingHeight / isi.wrapper.clientHeight * (isi.wrapper.clientHeight / isi.wrapper
            .scrollHeight);
          this.indicatorHeight = this.scale * sbBoundingHeight;
          this.indicator.style.height = this.indicatorHeight + 'px';
        },
        correction: function () {
          if (!this.isHeightCorrected) {
            this.isHeightCorrected = true;
            this.calc();
          }
        }
      }
      scrollBar.calc();
      waitImagesAndStartScroll();

      function waitImagesAndStartScroll() {
        const _documentImgs = 0;
        let _imgsLoadedCounter = 0;
        if (_documentImgs.length > 0) {
          [].forEach.call(_documentImgs, function (img) {
            if (img.complete) {
              incrementCounter();
            } else {
              img.addEventListener('load', incrementCounter, false);
            }
          });
        } else {
          loadScrolls();
        }

        function incrementCounter() {
          _imgsLoadedCounter++;
          if (_imgsLoadedCounter === _documentImgs.length) {
            loadScrolls();
          }
        }
      }

      function loadScrolls() {
        function startListenManualScroll() {
          isi.wrapper.addEventListener('wheel', normalScroll, { passive: true });
          isi.wrapper.addEventListener('click', normalScroll);
          isi.wrapper.addEventListener('touchstart', normalScroll, { passive: true });
          scrollBar.indicator.addEventListener('mousedown', startDragVScroll);
          scrollBar.indicator.addEventListener('touchstart', startDragVScroll, { passive: true });
        }
        if (isi.scrollDiff > 0) {
          if (browserIsIE) {
            // ie 11 first load fix by set timeout
            setTimeout(function () {
              initVerticalScroll();
            }, 700)
          } else {
            initVerticalScroll();
          }
        } else {
          scrollBar.container.remove();
        }

        function initVerticalScroll() {
          isi.calcScrollDiff();
          scrollBar.calc();
          // indicator height fix for multi isi banners
          if (sbih === 'undefined') {
            sbih = scrollBar.indicator.style.height;
          }
          if (conf.scrollType !== 'auto' && conf.scrollType !== 'after') {
            startListenManualScroll()
          }
          if (conf.scrollTime > 0 && conf.scrollType !== 'manual') {
            conf.scrollDelay += 300;
            setTimeout(autoScrollStart, conf.scrollDelay);
          }
        }

        function startDragVScroll(e) {
          scrollBar.correction();
          isi.wrapper.classList.add('not-selectable');
          if (e.type === 'touchstart') {
            scrollBar.lastTouchY = e.touches[0].clientY;
          } else {
            scrollBar.lastEventY = e.clientY;
          }
          isi.wrapper.removeEventListener('touchstart', normalScroll);
          scrollBar.indicator.removeEventListener('mousedown', startDragVScroll);
          scrollBar.indicator.removeEventListener('touchstart', startDragVScroll);
          window.addEventListener('mouseup', stopDragVScroll);
          isi.wrapper.addEventListener('mousemove', dragVScroll);
          isi.wrapper.addEventListener('touchmove', dragVScroll);
          isi.wrapper.addEventListener('touchend', stopDragVScroll);
        }

        function dragVScroll(e) {
          let posY;
          let posDiff;
          if (e.type === 'touchmove') {
            posY = e.touches[0].clientY;
            posDiff = (posY - scrollBar.lastTouchY) / scrollBar.scale;
            scrollBar.lastTouchY = posY;
          } else {
            posY = e.clientY;
            posDiff = (posY - scrollBar.lastEventY) / scrollBar.scale;
            scrollBar.lastEventY = posY;
          }
          autoScrollEnd();
          setScrollVal(isi.prevOffTop - posDiff);
        }

        function stopDragVScroll(e) {
          isi.wrapper.classList.remove('not-selectable');
          if (e.type === 'touchend') {
          }
          isi.wrapper.addEventListener('touchstart', normalScroll);
          window.removeEventListener('mouseup', stopDragVScroll);
          isi.wrapper.removeEventListener('mousemove', dragVScroll);
          isi.wrapper.removeEventListener('touchend', stopDragVScroll);
          isi.wrapper.removeEventListener('touchmove', dragVScroll);
          scrollBar.indicator.addEventListener('mousedown', startDragVScroll);
          scrollBar.indicator.addEventListener('touchstart', startDragVScroll);
        }

        function autoScrollStart() {
          isi.calcScrollDiff();
          autoScroll.isProcess = true;
          scrollBar.correction();
          const err = (document.getElementById("scrollspeed")) ? (document.getElementById("scrollspeed").innerText) :
            "";
          const scrollTime = (err == "scrollspeed") ? (parseInt(conf.scrollTime / 400)) : (parseInt(conf.scrollTime /
            300));
          isi.scroller.style.transition = 'transform ' + scrollTime + 's linear';
          scrollBar.indicator.style.transition = 'transform ' + scrollTime + 's linear';
          setScrollVal(-isi.scrollDiff);
          window._intervalTransform = setInterval(function () {
            autoScroll.timeSpend += autoScroll.transformInterval;
            isi.prevOffTop = -parseInt(autoScroll.timeSpend / conf.scrollTime * isi.scrollDiff);
          }, autoScroll.transformInterval);
          const delaytime = parseInt(conf.scrollTime) + 370000;
          setTimeout(autoScrollEnd, delaytime);
        }

        function autoScrollEnd() {
          if (!autoScroll.isProcess) {
            return;
          }
          if (conf.scrollType === 'after') {
            startListenManualScroll()
          }
          autoScroll.isProcess = false;
          if (conf.scrollType === 'manual') {
            return;
          }
          clearTimeout(autoScrollStart);
          clearInterval(window._intervalTransform);
          isi.scroller.style.transition = '';
          scrollBar.indicator.style.transition = '';
          isi.scroller.style.transform = 'translateY(0px) translateZ(0px)';
          scrollBar.indicator.style.transform = 'translateY(0px) translateZ(0px)';
        }

        function normalScroll(e) {
          autoScrollEnd();
          let deltaY = 0;
          if (e.type === 'touchstart') {
            isi.prevTouchY = e.touches[0].clientY;
            isi.wrapper.addEventListener('touchmove', normalScroll);
            isi.wrapper.addEventListener('touchend', normalScroll);
            scrollBar.indicator.removeEventListener('touchstart', startDragVScroll);
            return;
          } else if (e.type === 'touchend') {
            isi.wrapper.removeEventListener('touchmove', normalScroll);
            isi.wrapper.removeEventListener('touchend', normalScroll);
            scrollBar.indicator.addEventListener('touchstart', startDragVScroll);
            return;
          } else if (e.type === 'click') {
            deltaY = 0;
          } else if (typeof e.deltaY !== "undefined") {
            deltaY = e.deltaY;
          } else if (typeof e.touches !== "undefined" && typeof e.touches[0] !== "undefined" && typeof e.touches[0]
            .clientY !== "undefined") {
            deltaY = -(e.touches[0].clientY - isi.prevTouchY);
            isi.prevTouchY = e.touches[0].clientY;
          }
          setScrollVal(isi.prevOffTop - deltaY);
        }

        function setScrollVal(val) {
          if (val < -isi.scrollDiff) {
            val = -isi.scrollDiff;
          } else if (val > 0) {
            val = 0;
          }
          isi.scroller.style.transform = 'translateY(' + val + 'px) translateZ(0px)';
          scrollBar.indicator.style.transform = 'translateY(' + Math.abs(val) * scrollBar.scale + 'px) translateZ(0px)';
          if (!autoScroll.isProcess) {
            isi.prevOffTop = val;
          }
        }
      }
    }
  </script>
  <style>
    .iScrollHorizontalScrollbar {
      position: absolute;
      z-index: 9999;
      height: 20px;
      left: 2px;
      right: 2px;
      bottom: 2px;
      overflow: hidden;
    }

    .iScrollHorizontalScrollbar.iScrollBothScrollbars {
      right: 20px;
    }

    .iScrollVerticalScrollbar {
      position: absolute;
      z-index: 9999;
      width: 2px;
      bottom: 4px;
      top: 29px;
      right: 5px;
      overflow: hidden;
      background: rgba(217, 217, 217, 1);
      border-radius: 8px;
    }

    .iScrollVerticalScrollbar.iScrollBothScrollbars {
      bottom: 18px;
    }

    .iScrollIndicator {
      position: absolute;
      background: #064264;
      width: 2px;
      border-radius: 8px;
    }

    .bmsLogo {
      width: 170px;
    }

    .block {
      display: inline-block;
    }
  </style>

</div>

      </div>
    </div>
  </div>

  <script>
    setTimeout("contentScroll()", 15000);

    function contentScroll() {
      if (!functionIsRunning) {
        autoscroll();
      }
    }
  </script>
   <script>
    // DoubleClick img pixel with cache busting
    var doubleclickPixel = document.createElement("img");
    doubleclickPixel.setAttribute("width", "1");
    doubleclickPixel.setAttribute("height", "1");
    doubleclickPixel.setAttribute("border", "0");
    doubleclickPixel.setAttribute("alt", "Advertisement");
    doubleclickPixel.setAttribute("attributionsrc", "");
    doubleclickPixel.setAttribute("src", "https://ad.doubleclick.net/ddm/trackimp/N6246.3434815PRIHEALTHCARESOLUTI/B32782690.412475170;dc_trk_aid=604689260;dc_trk_cid=229088979;ord=" + Date.now() + ";dc_rdid=;tag_for_child_directed_treatment=;tfua=;gdpr=${GDPR};gdpr_consent=${GDPR_CONSENT_755};ltd=;dc_tdv=1?");
    document.body.appendChild(doubleclickPixel);
  </script>
</body>

</html>
